Functional exhaustion of CD4+ T cells induced by co‐stimulatory signals from myeloid leukaemia cells

No abstract is available for this paper.

• Publication year

  2016

• Venue

  Immunology

• Publication date

  2016-12-01

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1111/imm.12665PMID 27565576PMCID PMC5095494
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• PD-1hiTIM-3+ T cells associate with and predict leukemia relapse in AML patients post allogeneic stem cell transplantation

  2015cited by this paper
• Adaptive Immune Resistance: How Cancer Protects from Immune Attack.

  2015cited by this paper
• TIM-3/Gal-9 interaction induces IFNγ-dependent IDO1 expression in acute myeloid leukemia blast cells

  2015cited by this paper
• T cell exhaustion, costimulation and clinical outcome in autoimmunity and infection

  2015cited by this paper
• Exhaustion of bacteria-specific CD4 T cells and microbial translocation in common variable immunodeficiency disorders

  2014cited by this paper
• T cell differentiation in chronic infection and cancer: functional adaptation or exhaustion?

  2014cited by this paper
• Homeostatic control of regulatory T cell diversity

  2014cited by this paper
• Coexpression of CD49b and LAG-3 identifies human and mouse T regulatory type 1 cells

  2013cited by this paper
• TIM3+FOXP3+ regulatory T cells are tissue-specific promoters of T-cell dysfunction in cancer

  2013cited by this paper
• Myeloid leukemia cells with a B7‐2+ subpopulation provoke Th‐cell responses and become immuno‐suppressive through the modulation of B7 ligands

  2013cited by this paper
• T cell anergy, exhaustion, senescence, and stemness in the tumor microenvironment.

  2013cited by this paper
• Restoring Immune Function of Tumor-Specific CD4+ T Cells during Recurrence of Melanoma

  2013cited by this paper
• Oncology meets immunology: the cancer-immunity cycle.

  2013cited by this paper
• Adaptive resistance: A tumor strategy to evade immune attack

  2013cited by this paper
• T cells from CLL patients exhibit features of T-cell exhaustion but retain capacity for cytokine production.

  2013cited by this paper
• Tumor-specific CD4+ T cells maintain effector and memory tumor-specific CD8+ T cells

  2013cited by this paper
• Inhibitory Receptor Expression Depends More Dominantly on Differentiation and Activation than “Exhaustion” of Human CD8 T Cells

  2013cited by this paper
• Functional Exhaustion of CD4+ T Lymphocytes during Primary Cytomegalovirus Infection

  2012cited by this paper
• The Role of Antigen Cross-presentation From Leukemia Blasts on Immunity to the Leukemia-associated Antigen PR1

  2012cited by this paper
• Reduced tumor‐antigen density leads to PD‐1/PD‐L1‐mediated impairment of partially exhausted CD8+ T cells

  2012cited by this paper
• PD-1/PD-L1 interactions contribute to functional T-cell impairment in patients who relapse with cancer after allogeneic stem cell transplantation.

  2011cited by this paper
• Coexpression of Tim-3 and PD-1 identifies a CD8+ T-cell exhaustion phenotype in mice with disseminated acute myelogenous leukemia.

  2011cited by this paper
• Natural innate and adaptive immunity to cancer.

  2011cited by this paper
• T‐bet, a Th1 transcription factor regulates the expression of Tim‐3

  2010cited by this paper
• T cell activation.

  2009cited by this paper
• Programmed death 1 signaling on chronic myeloid leukemia-specific T cells results in T-cell exhaustion and disease progression.

  2007cited by this paper
• The B7 Family and Cancer Therapy: Costimulation and Coinhibition

  2007cited by this paper
• Molecular signature of CD8+ T cell exhaustion during chronic viral infection.

  2007cited by this paper
• Prolonged TCR/CD28 Engagement Drives IL-2-Independent T Cell Clonal Expansion through Signaling Mediated by the Mammalian Target of Rapamycin1

  2006cited by this paper
• High expression of costimulatory molecules correlates with low relapse-free survival probability in acute myeloid leukemia (AML)

  2005cited by this paper
• Expression of Functional B7-H2 and B7.2 Costimulatory Molecules and Their Prognostic Implications in De novo Acute Myeloid Leukemia

  2005cited by this paper
• Phenotypic and functional differences between human CD4+CD25+ and type 1 regulatory T cells.

  2005cited by this paper
• CTLA-4 and PD-1 Receptors Inhibit T-Cell Activation by Distinct Mechanisms

  2004cited by this paper
• Lymphocyte Activation Gene-3 (CD223) Regulates the Size of the Expanding T Cell Population Following Antigen Activation In Vivo1

  2004cited by this paper
• Leukemia-Derived Immature Dendritic Cells Differentiate into Functionally Competent Mature Dendritic Cells That Efficiently Stimulate T Cell Responses1

  2004cited by this paper
• Exhaustion of cytotoxic T cells during adoptive immunotherapy of virus carrier mice can be prevented by B cells or CD4+ T cells

  2002cited by this paper
• Interleukin-7: master regulator of peripheral T-cell homeostasis?

  2001cited by this paper
• The expression of co-stimulatory molecules and their relationship to the prognosis of human acute myeloid leukaemia : poor prognosis of B7-2-positive leukaemia

  1999cited by this paper
• The expression of co‐stimulatory molecules and their relation‐ ship to the prognosis of human acute myeloid leukaemia: poor prognosis of B7‐2‐positive leukaemia

  1998cited by this paper
• Expression of costimulatory molecules in human leukemias.

  1996cited by this paper
• T-cell activation.

  1992cited by this paper
• Cellular and Molecular Immunology

  1992cited by this paper

• Dysfunctional CD4 T cells in an oncovirus-specific TCR-transgenic in vivo model

  2025cites this paper
• In search of a targetable immune profile for acute myeloid leukemia.

  2025cites this paper
• Multi-compartment immune cell profiling highlights the prognostic relevance of CD127+ CD8+ T cells for patients with high-grade serous ovarian cancer

  2025cites this paper
• The discussion on the differences in immune microenvironment between low-risk and high-risk myelodysplastic syndromes and acute myeloid leukemia

  2025cites this paper
• Unveiling the power of plumbagin: revitalizing exhausted T cells to combat tongue cancer

  2025cites this paper
• CTLA-4 blockade in ovarian cancer immunotherapy: Mechanisms and clinical strategies.

  2025cites this paper
• Dynamic monitoring of lymphocyte subsets at different disease stages can predict the prognosis of acute myeloid leukemia especially in complete remission status

  2025cites this paper
• Impact of single nucleotide polymorphisms of immunomodulatory factors on treatment response and prognosis in acute myeloid leukemia

  2025cites this paper
• Isoalantolactone induces AML pyroptosis and potentiates α-PD-1 efficacy by targeting selenoprotein TXNRD1

  2025cites this paper
• Acquired immune resistance is associated with interferon signature and modulation of KLF6/c‐MYB transcription factors in myeloid leukemia

  2024influential citation
• Aging Deteriorates Blood Brain Barrier Function and Polarizes Adaptive T Cell Expansion Contributing to Neurocognitive Damage in Experimental Cirrhosis

  2024cites this paper
• Cellular and immunotherapies for myelodysplastic syndromes.

  2024cites this paper
• The molecular landscape of T cell exhaustion in the tumor microenvironment and reinvigoration strategies

  2024cites this paper
• T cell exhaustion and senescence for ovarian cancer immunotherapy.

  2024cites this paper
• Ex vivo characterization of acute myeloid leukemia patients undergoing hypomethylating agents and venetoclax regimen reveals a venetoclax-specific effect on non-suppressive regulatory T cells and bona fide PD-1+TIM3+ exhausted CD8+ T cells

  2024cites this paper
• The role of TIM-3 in sepsis: a promising target for immunotherapy?

  2024cites this paper
• The Role of BCL-2 and PD-1/PD-L1 Pathway in Pathogenesis of Myelodysplastic Syndromes

  2023cites this paper
• Targeting apoptosis dysregulation in myeloid malignancies - The promise of a therapeutic revolution.

  2023cites this paper
• T-cell dysfunction in natural killer/T-cell lymphoma

  2023cites this paper
• CD86 Is Associated with Immune Infiltration and Immunotherapy Signatures in AML and Promotes Its Progression

  2023cites this paper
• PARP9 knockdown confers protection against chemoresistance and immune escape of breast cancer cells by blocking the PI3K/AKT pathway

  2023cites this paper
• Association of TIM-3 checkpoint receptor expression on T cells with treatment-free remission in chronic myeloid leukemia

  2023cites this paper
• Lymphocyte Activation Gene 3 Single-Nucleotide Polymorphisms in Bone Marrow Failure Diseases

  2022cites this paper
• Immune Checkpoint Molecules and Glucose Metabolism in HIV-Induced T Cell Exhaustion

  2022cites this paper
• Landscape of alterations in the checkpoint system in myelodysplastic syndrome and implications for prognosis

  2022cites this paper
• An inflammatory response-related gene signature associated with immune status and prognosis of acute myeloid leukemia.

  2022cites this paper
• Immunodepletion of MDSC by AMV564, a novel bivalent, bispecific CD33/CD3 T cell engager, ex vivo in MDS and melanoma

  2022cites this paper
• Effector Th1 cells under PD‐1 and CTLA‐4 checkpoint blockade abrogate the upregulation of multiple inhibitory receptors and by‐pass exhaustion

  2022cites this paper
• Pan‐cancer analysis identifies CD300 molecules as potential immune regulators and promising therapeutic targets in acute myeloid leukemia

  2022cites this paper
• Combination of genetically engineered T cells and immune checkpoint blockade for the treatment of cancer

  2022cites this paper
• Comprehensive Analysis of N6-Methyladenosine-Related Long Noncoding RNA Prognosis of Acute Myeloid Leukemia and Immune Cell Infiltration

  2022influential citation
• Targeting PD-1/PD-L1 pathway in myelodysplastic syndromes and acute myeloid leukemia

  2022influential citation
• Immunosuppression and Outcomes in Acute Myeloid Leukemia

  2021cites this paper
• Molecular Targeted Therapy in Myelodysplastic Syndromes: New Options for Tailored Treatments

  2021cites this paper
• Development of a poor-prognostic-mutations derived immune prognostic model for acute myeloid leukemia

  2021cites this paper
• Immunosuppressive Cell Subsets and Factors in Myeloid Leukemias

  2021cites this paper
• CD4 T-Cell Exhaustion: Does It Exist and What Are Its Roles in Cancer?

  2021cites this paper
• TIM-3 in Leukemia; Immune Response and Beyond

  2021influential citation
• Immunosuppression and outcomes in adult patients with de novo acute myeloid leukemia with normal karyotypes

  2021cites this paper
• Randomized trials with checkpoint inhibitors in acute myeloid leukaemia and myelodysplastic syndromes: What have we learned so far and where are we heading?

  2020cites this paper
• Immune checkpoint inhibition in myeloid malignancies: Moving beyond the PD-1/PD-L1 and CTLA-4 pathways.

  2020cites this paper
• Immune checkpoints in hematologic malignancies: What made the immune cells and clinicians exhausted!

  2020cites this paper
• B7-Positive and B7-Negative Acute Myeloid Leukemias Display Distinct T Cell Maturation Profiles, Immune Checkpoint Receptor Expression, and European Leukemia Net Risk Profiles

  2020cites this paper
• Expression, Regulation and Function of microRNA as Important Players in the Transition of MDS to Secondary AML and Their Cross Talk to RNA-Binding Proteins

  2020cites this paper
• Ex vivo enrichment of PRAME antigen‐specific T cells for adoptive immunotherapy using CD137 activation marker selection

  2020cites this paper
• Higher frequency of the CTLA‐4+LAG‐3+ T‐cell subset in patients with newly diagnosed acute myeloid leukemia

  2020cites this paper
• Implications of Immune Checkpoint Expression During Aging in HIV-Infected People on Antiretroviral Therapy

  2019cites this paper
• SLAMF6 deficiency augments tumor killing and skews toward an effector phenotype revealing it as a novel T cell checkpoint

  2019cites this paper
• Exhaustion and senescence: two crucial dysfunctional states of T cells in the tumor microenvironment

  2019cites this paper
• Assay and Isolation of Single Proliferating CD4+ Lymphocytes Using an Automated Microraft Array Platform

  2019cites this paper
• Role of Inducible Co-Stimulator (ICOS) in cancer immunotherapy

  2019cites this paper
• Myeloid maturation potentiates STAT3-mediated atypical IFN-γ signaling and upregulation of PD-1 ligands in AML and MDS

  2019cites this paper
• Exhausted and Senescent T Cells at the Maternal-Fetal Interface in Preterm and Term Labor

  2019cites this paper
• Immune checkpoint-based therapy in myeloid malignancies: a promise yet to be fulfilled

  2019cites this paper
• Therapeutic Antibodies for Myeloid Neoplasms—Current Developments and Future Directions

  2018cites this paper
• Inducible Co-Stimulator (ICOS) as a potential therapeutic target for anti-cancer therapy

  2018cites this paper
• Biomarkers for checkpoint inhibition in hematologic malignancies.

  2018cites this paper
• CD33-Specific Chimeric Antigen Receptor T Cells with Different Co-Stimulators Showed Potent Anti-Leukemia Efficacy and Different Phenotype

  2018cites this paper
• Increased serum levels of Galectin-9 in patients with chronic lymphocytic leukemia

  2018cites this paper
• Targeting Immune Checkpoint Molecules to Eliminate Latent HIV

  2018cites this paper
• Transcriptome profiling analysis of grouper during nervous necrosis virus persistent infection

  2018cites this paper
• Checkpoint inhibitors and acute myelogenous leukemia: promises and challenges

  2018influential citation
• Leukemia cell-derived microvesicles induce T cell exhaustion via miRNA delivery

  2018cites this paper
• Reciprocal interactions between Leishmania and their microenvironments during infection in the sand fly gut and human macrophages

  2017cites this paper
• Co-Signaling Molecules in Maternal-Fetal Immunity.

  2017cites this paper
• Tumor-infiltrating CD4+ T cells in patients with gastric cancer

  2017cites this paper
• The Triple Immune Argument; Surveillance/Evasion/ Senescence and the Increased Incidence of Acute Myeloid Leukemia Observed with Age

  2017cites this paper
• A Co-Inhibitory Alliance in Myeloid Leukemia: TIM-3/Galectin-9 Complex as a New Target for Checkpoint Blockade Therapy

  2017cites this paper
• Higher PD-1 expression concurrent with exhausted CD8+ T cells in patients with de novo acute myeloid leukemia.

  2017cites this paper
• Functional expression of Tim-3 on blasts and clinical impact of its ligand galectin-9 in myelodysplastic syndromes

  2017cites this paper
• Tim-3 inhibits low-density lipoprotein-induced atherogenic responses in human umbilical vein endothelial cells

  2017cites this paper